Drug Database
IN

infliximab (Anbaite / HS626 / HS 626)

✓ Approved

Zhejiang Hisun Pharmaceutical Co., Ltd. · TNF · Monoclonal Antibodies

What is infliximab?

infliximab is a monoclonal antibodies developed by Zhejiang Hisun Pharmaceutical Co., Ltd.. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesAnbaite, HS626, HS 626
CompanyZhejiang Hisun Pharmaceutical Co., Ltd.
Drug ClassMonoclonal Antibodies, Antibody
Molecular TargetTNF
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Zhejiang Hisun Pharmaceutical Co., Ltd.

Mechanism of Action

Molecular Targets

infliximab acts on 1 molecular target:

TNFtumor necrosis factor (TNFA, TNF-alpha)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

infliximab is developed for 5 unique indications across 3 therapeutic areas.

Therapeutic AreaConditionPhase
Musculoskeletal and connective tissue disordersAnkylosing spondylitis✓ Approved
Gastrointestinal disordersColitis ulcerative✓ Approved
Gastrointestinal disordersCrohn's disease✓ Approved
Skin and subcutaneous tissue disordersPsoriasis✓ Approved
Musculoskeletal and connective tissue disordersRheumatoid arthritis✓ Approved

Related Research Articles

PubMedEuropean journal of case reports in internal medicine2026-07-17

Effective Treatment of Audiovestibular Involvement in Cogan's Syndrome with Biologics and Hyperbaric Oxygen Therapy.

Biadacz-Sadurska Angelika A, Krefta Anna A, Tłustochowicz Witold W

Cogan's syndrome is a rare autoimmune disease typically affecting the ocular and audiovestibular system. Inner ear involvement is associated with a poor prognosis, as despite therapy, over 50% of patients develop profound deafness. The standard treatment remains the use of high dose glucocorticosteroids and immunosuppressants. Studies from recent years have reported significantly higher rates of improvement and recovery among patients treated with biologic disease modifying antirheumatic drugs (bDMARDs), particularly infliximab. We report the case of a 39-year-old Caucasian female who experienced bilateral interstitial keratitis, sudden hearing loss, labyrinthine symptoms and arthralgia. Based on the clinical picture, Cogan's syndrome was diagnosed. Initial treatment included high doses of glucocorticosteroids which did not result in a satisfactory clinical response. Due to the high risk of permanent deafness, it was decided to administer infliximab. Simultaneously, subcutaneous methotrexate was introduced, and the patient was referred for hyperbaric oxygen therapy. Follow-up hearing tests conducted four weeks later revealed a significant improvement. As a result of the treatment, hearing normalized and labyrinthine and ophthalmological as well as systemic symptoms disappeared. Considering the unfavourable prognosis in Cogan's syndrome with vestibulocochlear involvement, it seems reasonable to quickly escalate treatment if there is no sufficient response to glucocorticosteroids within two weeks. Infliximab has the most documented effectiveness among DMARDs. Combining pharmacotherapy with HBOT can significantly improves treatment outcomes. Improved prognosis This case highlights a potential therapeutic strategy that may improve outcomes in patients with Cogan's syndrome and reduce the risk of disability.Disease reminder Knowledge of this rare disease is essential so that the internist, in cooperation with the otolaryngologist and ophthalmologist, can quickly make the appropriate diagnosis and implement intensive treatment.

PMID 42466223
Read full article →
PubMedBMC gastroenterology2026-07-17

Hepatic and splenic tuberculosis following infliximab therapy for refractory ulcerative colitis: a case report and literature review.

Chen Shuo S, Shi Yanfen Y, Pang Yang Y, Wang Xiaodi X et al.

Tumor necrosis factor-α (TNF-α) inhibitors are first-line agents for steroid-refractory/resistant ulcerative colitis (UC), but their immunosuppressive effect elevates the risk of opportunistic infections, particularly tuberculosis (TB). Extrapulmonary TB such as hepatic and splenic TB is rare but prone to misdiagnosis. A 55-year-old male was diagnosed with UC in 2003, relieved by sulfasalazine and mesalazine for recurrence in 2021. In 2024, post-perianal abscess surgery, UC relapsed with positive cytomegalovirus (CMV), treated with glucocorticoids and ganciclovir. The patient subsequently developed glucocorticoid-dependent acute severe active UC, presenting with more than 10 bloody stools per day and a Mayo endoscopic score of 3 points. The patient failed to achieve symptom relief after one week of vedolizumab treatment, prompting an immediate adjustment of the therapeutic strategy, and infliximab was therefore initiated. After 6 infliximab doses, he developed fever. T-SPOT/PPD turned positive, with liver and spleen nodules. Biopsy showed epithelioid granulomatous inflammation, Xpert mycobacterium TB/RIF test was positive, leading to hepatic/splenic TB diagnosis. Quadruple anti-TB therapy was initiated. UC relapsed in December 2025, improved by guselkumab. Anti-tuberculosis treatment continues with planned re-evaluation after 1 year. Hepatic/splenic TB lacks specificity, often mimicking drug-induced liver injury. Latest guidelines emphasize baseline TB screening (PPD + TSPOT.TB + chest CT) and 3-6 monthly surveillance during biologic use. Anti-TB drugs may exert synergistic anti-UC effects via cytokine inhibition. Extrapulmonary TB requires ≥ 12 months of anti-TB therapy. Clinicians should remain alert to hepatic/splenic TB in UC patients receiving biologic therapy, particularly those with sequential biologic exposure. Timely pathological and etiological diagnosis and anti-TB therapy improve prognosis, with strict TB surveillance crucial for early detection.

PMID 42464147
Read full article →
PubMedMolecular and cellular pediatrics2026-07-17

Subcutaneous infliximab as a maintenance option in pediatric IBD: a real-world cohort including younger and lower-weight children.

Ridder Neele N, Overberg Johanna J, Kalveram Laura L, Pudasaini Samipa S et al.

Subcutaneous infliximab (SC-IFX) offers an alternative to intravenous infliximab (IV-IFX) in adults with inflammatory bowel disease (IBD), but evidence in children is scarce. This study reports treatment persistence, tolerability, and pharmacokinetics in a real-world pediatric IBD cohort following transition from IV-IFX. We conducted a single center retrospective study including all pediatric IBD patients transitioned from IV-IFX to SC-IFX (120 mg every other week) at our institution between November 2023 and April 2025. Clinical disease activity scores, inflammatory markers, IFX serum concentrations, and anti-IFX antibodies (AIA) were assessed at baseline and during follow-up. The primary outcome was treatment persistence. Secondary outcomes included disease activity, pharmacokinetics, immunogenicity and tolerability. Twenty patients (median age 14.5 years; range 5-17), including six children < 12 years and five weighing < 40 kg, were included. After a median observation period of 44 weeks (IQR 26-60), 16/20 patients (80%) remained on SC-IFX, with no significant difference between Crohn's disease and ulcerative colitis. In a subgroup of four patients who received SC-IFX as a third dose following two intravenous induction doses, 3/4 (75%) maintained treatment over a median observation period of 60 weeks (range 16-64 weeks) and remained in clinical remission during follow-up. IFX serum concentrations increased after switching (median 11.8 µg/mL pre-switch vs. ≥24 µg/mL at follow-up), with most follow-up measurements reaching the assay ceiling. Concentrations were descriptively comparable between weight groups. All patients with detectable AIA prior to switching became antibody-negative during SC-IFX therapy, and no de novo antibodies were observed. Two patients discontinued therapy due to worsening of pre-existing paradoxical psoriasis. No other adverse events were documented. SC-IFX showed high persistence, stable inflammatory markers and good tolerability in this pediatric cohort, including younger and lower-weight children. SC-IFX appears to be a feasible maintenance option in selected pediatric patients, including early use after induction. Prospective studies are warranted to define pediatric-specific pharmacokinetic targets and individualized dosing strategies.

PMID 42463592
Read full article →
PubMedCrohn's & colitis 3602026-07-16

Real-world outcomes of subcutaneous infliximab in a Middle Eastern inflammatory bowel disease cohort: a prospective study of switch and de novo treatment strategies.

Alahmad Maryam A MA, Omar Nadeen Mamon NM, Quraishi Mohammed Nabil MN

Subcutaneous (SC) infliximab offers pharmacokinetic and convenience advantages over intravenous (IV) therapy, but real-world data from the Middle East are lacking. This study evaluated SC infliximab outcomes in a prospective middle eastern inflammatory bowel disease (IBD) cohort. A prospective observational cohort study was conducted in the United Arab Emirates. Adult IBD patients were enrolled as switchers (transitioning from stable IV to SC infliximab 120 or 240 mg Q2W) or new starters (SC 120 mg Q2W following IV induction). Clinical outcomes and pharmacokinetics were assessed. Fifty-eight patients were included (33 switchers [10 receiving 120 mg Q2W, 23 receiving 240 mg Q2W] and 25 new starters), with median follow-up of 10.1 months (interquartile range [IQR] 7.3-12.9). In the switcher cohort, 90.9% maintained clinical remission post-switch, with stable C-reactive protein (CRP), serum albumin, and fecal calprotectin, and significant increases in median trough concentrations: 9.5-20.0 mcg/mL in the 120 mg group (P = .044) and 8.0-42.0 mcg/mL in the 240 mg group (P = .001). Among new starters, 88% achieved clinical remission post-induction, with a median post-induction trough level of 16.0 mcg/mL; significant improvements in CRP, serum albumin, and fecal calprotectin were observed. Dose intensification was required in 28% of new starters. Drug persistence was high and comparable across all groups (log-rank P = .61), with 12-month rates of over 92% across all cohorts. SC infliximab is effective for both switching and de novo IBD management in a middle eastern population, delivering high clinical remission rates, robust drug exposure, and durable treatment persistence.

PMID 42459865
Read full article →
PubMedOcular immunology and inflammation2026-07-16

Ocular Involvement in Childhood-Onset Sarcoidosis: A Case Series.

Rees Amelia A, Noor Maha M, Olatunji Patrick P, Varnier Giulia G et al.

Childhood-onset sarcoidosis (COS) is a rare granulomatous autoinflammatory condition characterised by arthritis, dermatitis, and uveitis which includes early-onset forms (sporadic or Blau syndrome) and a later-onset form resembling adult sarcoidosis. Ocular involvement often occurs early and may be a prominent, sight-threatening feature. Despite this, COS is sparsely described in the literature. This case series aims to characterise the ocular manifestations, complications, and outcomes in COS. A review of patients diagnosed with COS under a tertiary paediatric uveitis service. Data collected included age at onset, clinical findings, diagnostic methods, treatments, ocular complications, and visual acuity (VA) at presentation and last follow-up. Six patients were identified, all of whom presented with granulomatous uveitis. Four had posterior segment involvement including choroiditis and optic disc swelling. The mean age of ocular disease onset was 7 years. Diagnosis was supported by elevated serum angiotensin converting enzyme (ACE) followed by lymph node biopsy (n = 3), skin biopsy (n = 2), and/or NOD2 mutation (n = 3). All received systemic immunosuppression: methotrexate (n = 6), adalimumab (n = 5), mycophenolate (n = 2), oral corticosteroids (n = 3), and infliximab (n = 1). Complications included uveitic glaucoma (n = 2), cataract (n = 3), and chorioretinal scarring (n = 1). VA improved or remained stable in most, with one case of persistent visual impairment. COS-related uveitis demonstrates an aggressive, chronic course with early onset, bilateral involvement, and frequent complications with potential to cause visual loss. Careful ophthalmic screening in children with known or suspected sarcoidosis is critical.

PMID 42461878
Read full article →
PubMedJournal of Crohn's & colitis2026-07-15

Correction to: Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY).

PMID 42455704
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about infliximab